Nanobodies®

Nanobodies^®

Article Type: Food facts From: Nutrition & Food Science, Volume 41, Issue 2

Ablynx (Euronext Brussels: ABLX) and Merck Serono, a division of Merck KGaA,Darmstadt, Germany, have expanded their relationship and entered into a second agreement, to develop nanobodies against an inflammatory disease target.

Ablynx’s nanobodies are an innovative class of antibody-derived therapeutic proteins that combine the advantages of conventional antibodies with key properties of small molecule drugs such as high affinity, small size allowing alternative delivery and enhanced tissue penetration and high stability.